People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ra Medical Systems, Inc. | — | Biotechnology | Series C | $98.0M | $115.9M | 2016 |
| Eterna Therapeutics Inc. | — | Biotechnology | Series A | $53.1M | $26.5M | 2022 |
| AltheaDx, Inc. | — | Biotechnology | Series B | $51.8M | $137.3M | 2017 |
| Calidi Biotherapeutics, Inc. | — | Biotechnology | Series A | $15.2M | $30.2M | 2023 |
Andrew Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wei Li | 1 | 7 |
| Magda Marquet | 1 | 6 |
| Matthew Angel | 1 | 5 |
| Jason Liu | 1 | 4 |
| George Ng | 1 | 4 |
| Alan R. Stewart | 1 | 4 |
| J. Matthew Mackowski | 1 | 4 |
| David Nikodem | 1 | 4 |
| John Wu | 1 | 4 |
| Jeffrey Kraws | 1 | 3 |
| James A. Schoeneck | 1 | 3 |
| Charles Cherington | 1 | 3 |
| Richard W. Wagner | 1 | 3 |
| Maurice Buchbinder | 1 | 3 |
| Jeffrey G. Black | 1 | 3 |
| Gregory Fiore | 1 | 3 |
| Deval A Lashkari | 1 | 2 |
| James Bristol | 1 | 2 |
| James B Glavin | 1 | 2 |
| STEVE MITGANG | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.